Ardelyx (NASDAQ:ARDX) specializes in discovering, developing, and commercializing innovative medicines to improve treatment for people with kidney and cardiovascular diseases. The company is focused on addressing unmet medical needs, particularly in the realms of cardiorenal diseases, a term that refers to heart conditions that are caused or worsened by kidney problems. Ardelyx’s commitment is towards projects that leverage its unique understanding of kidney function and the mechanisms behind these conditions. Its main objectives include advancing its lead drug candidates through clinical trials, securing regulatory approvals, and establishing strategic partnerships to ensure the broadest possible access to its therapies.